STOCK TITAN

OneMedNet Corp Form 4 Filings

ONMD NASDAQ

Every Form 4 that OneMedNet Corp (ONMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow ONMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONMD filings page.

Rhea-AI Summary

OneMedNet Corp (ONMD) reported that Jeffrey Yu, a director, Chief Medical Officer and more-than-10% owner, entered into a subscription agreement to purchase 142,857 shares of common stock on September 10, 2026 for a $90,000 investment, valued at a $0.63 volume-weighted average price over the prior 10 trading days. Following this transaction, he holds 8,923,267 shares directly and an additional 1,311,970 shares are held indirectly in a trust for his children with an independent trustee; he disclaims beneficial ownership of the trust shares. No Rule 10b5-1 trading plan is reported.

Rhea-AI Summary

OneMedNet Corp reported that director and 10% owner Thomas Kosasa purchased 1,449,275 shares of common stock on July 30, 2026. The $1,000,000 investment was made through a subscription agreement, with the shares priced at $0.69 each, based on the volume-weighted average price for the 10 trading days immediately prior to the purchase date. Following the transaction, he directly owns 18,538,150 shares.

Rhea-AI Summary

OneMedNet Corp Chief Executive Officer Aaron Green reported an open-market purchase of 36,650 shares of the company’s Common Stock. The shares were bought at an average price of $0.5733 per share in a single transaction.

Following this purchase, Green directly holds 1,896,375 shares of OneMedNet Common Stock, indicating that the transaction modestly increased his existing ownership position.

Rhea-AI Summary

OneMedNet Corp Chief Medical Officer Jeffrey Yu reported a direct open-market purchase of 158,730 shares of Common Stock at $0.63 per share. This reflects a $100,000 investment under a subscription agreement dated June 23, 2026. After this transaction, he directly holds 8,780,410 shares. An additional 1,311,970 shares are held in a trust for his children with an independent trustee, where he has no investment control and disclaims beneficial ownership.

Rhea-AI Summary

OneMedNet Corp Chief Medical Officer Jeffrey Yu made a substantial open-market purchase of company stock. On June 16, 2026, he bought 172,414 shares of common stock at $0.58 per share under a subscription agreement for a $100,000 investment.

Following this purchase, Yu directly holds 8,621,680 shares of OneMedNet common stock. The filing also reports 1,311,970 shares held indirectly in a trust for his children with an independent trustee, for which he has no investment control and disclaims beneficial ownership.

Rhea-AI Summary

OneMedNet Corp director and CEO Aaron Green reported open-market purchases of the company’s Common Stock. On June 12, 2026, he bought 36,920 shares at an average price of $0.5581 per share. On June 15, 2026, he bought an additional 18,702 shares at an average price of $0.5396 per share.

After these transactions, Green directly owned 1,859,725 Common Stock shares. A footnote explains that one of the reported prices is a weighted average for multiple trades executed between $0.5463 and $0.5625 per share.

Rhea-AI Summary

OneMedNet Corp director and 10% owner Thomas Kosasa bought 158,730 shares of common stock at $0.63 per share. The $100,000 investment was made on June 12, 2026 through a subscription agreement, with the share price based on the 10-day volume-weighted average price. Following this purchase, Kosasa directly holds 17,088,874 shares of OneMedNet.

Rhea-AI Summary

OneMedNet Corp director and 10% owner Thomas Kosasa bought additional common stock. On May 18, 2026, he acquired 268,817 shares of OneMedNet common stock at a reported price of $0.93 per share, increasing his direct holdings to 16,930,144 shares.

The purchase was made through a $250,000 investment in OneMedNet under a subscription agreement, with the shares valued at the volume-weighted average price for the 10 trading days immediately before the purchase date.

Rhea-AI Summary

OneMedNet Corp director and Chief Medical Officer Jeffrey Yu increased his stake through a sizable cash investment and share grant. On April 1, 2026, he invested $750,000 in a subscription agreement, receiving 903,614 common shares at $0.83 each, and was issued 219,429 shares in lieu of prior cash compensation at the same price. Following these transactions, he directly owns 8,449,266 common shares. An additional 1,311,970 shares are held in a trust with an independent trustee, for which he disclaims beneficial ownership.

Rhea-AI Summary

OneMedNet Corp director and ten percent owner Thomas Kosasa increased his direct holdings through two stock purchases. On February 6, 2026, he bought 595,238 shares of common stock at $0.84 per share under a $500,000 subscription agreement. On April 23, 2026, he purchased 280,898 shares at $0.89 per share under a $250,000 subscription agreement. These transactions total 876,136 shares and $750,000 of investment, bringing his direct ownership to 16,661,327 common shares after the latest purchase. The purchase prices were based on the volume-weighted average price over the 10 trading days before each purchase date.

Rhea-AI Summary

OneMedNet Corp insider activity: a director and Chief Medical Officer reported multiple open-market purchases of OneMedNet common stock between December 8, 2023 and January 30, 2024, generally in small increments at prices ranging from about $0.48 to $1.36 per share, some reported as weighted average prices from multiple trades. On January 19, 2024, the insider also received 45,000 restricted stock units (RSUs) as director compensation under the 2022 Equity Incentive Plan for board service in fiscal year 2024; each RSU represents one share of common stock and vested on December 31, 2024. Following these transactions, the insider reported owning 2,507,351 shares directly and 1,311,970 shares indirectly through a trust for children with an independent trustee, for which beneficial ownership is disclaimed.